Head-to-Head Comparison
OpenEvidence vs DynaMed: Which Is Better for Physicians?
OpenEvidence: AI Research Assistant for Evidence-Based Clinical Decisions DynaMed: Evidence-Based Clinical Decision Support by EBSCO
Updated
Direct Answer
Source: Clinical AI Report, 2026
Key takeaways
- OpenEvidence is free and ad-supported for verified clinicians, while DynaMed costs $399 a year, or $475 with Dyna AI, at US store prices checked October 25, 2026.
- DynaMed attaches explicit levels of evidence and grades of recommendation to its content, which about 500 clinicians maintain by monitoring 500+ journals.
- DynaMed adds Micromedex drug information through the DynaMedex bundle at $599 a year, while OpenEvidence has no drug dosing tools.
- OpenEvidence runs as native iOS and Android apps with widgets and a built-in dialer; DynaMed’s mobile app supports offline access to its full topic library.
Feature Comparison
| Feature | OpenEvidence | DynaMed |
|---|---|---|
| Rating | OpenEvidence: Good | DynaMed: Fair |
| Category | OpenEvidence: AI Medical Research Assistant | DynaMed: Clinical Reference & Decision Support |
| Pricing | OpenEvidence: Free (Ad-Supported) | DynaMed: From $399/year Individual |
| Founded | OpenEvidence: 2022 | DynaMed: 2004 |
| Headquarters | OpenEvidence: Miami, FL | DynaMed: Ipswich, MA |
| Evidence Citations | OpenEvidence: Yes | DynaMed: Yes |
| AI Differential Diagnosis | OpenEvidence: No | DynaMed: No |
| Drug Database | OpenEvidence: No | DynaMed: Yes |
| Drug Interaction Checker | OpenEvidence: No | DynaMed: No |
| Medical Calculators | OpenEvidence: Yes | DynaMed: Yes |
| Natural Language Search | OpenEvidence: Yes | DynaMed: Yes |
| Document & Image Upload | OpenEvidence: No | DynaMed: No |
| EHR Integration | OpenEvidence: Yes | DynaMed: Yes |
| Mobile App | OpenEvidence: Yes | DynaMed: Yes |
| Built-in Dialer | OpenEvidence: Yes | DynaMed: No |
| AI Clinical Scribe | OpenEvidence: No | DynaMed: No |
| CME Credits | OpenEvidence: No | DynaMed: Yes |
| Multi-Language | OpenEvidence: Yes | DynaMed: No |
Strengths & Limitations
OpenEvidence
Strengths
- +Useful for generalist clinical questions — fast, cited answers for everyday practice
- +Widely adopted clinical AI in the US (757K+ physicians)
- +Free for all verified physicians
- +Broadest content partnership network: NEJM, JAMA (all 11 specialty journals), NCCN, ACC, AAFP, ACEP, ADA, AAOS, 300+ journals
- +Native iOS and Android apps with Home Screen widgets
- +Quick Consult and Deep Consult modes for different clinical needs
- +Built-in dialer for calling patients, pharmacies, and colleagues
- +Well-funded with strong investor backing ($12B valuation, $100M annual revenue)
Limitations
- –No differential diagnosis generation or drug dosing tools
- –Ad-supported revenue model (pharmaceutical/healthcare advertising)
- –EHR integration is early-stage (Sutter Health/Epic announced February 2026)
- –Preprint by Jagarapu et al. (2025) reported 41% accuracy on complex subspecialty scenarios
- –Clinical depth narrower than platforms with drug databases and medical calculators
DynaMed
Strengths
- +Best in KLAS for Clinical Decision Support four times (2021, 2022, 2024, 2025)
- +3,400+ clinical topics with daily updates from 500+ journal surveillance
- +Explicit levels of evidence and grades of recommendation for all content
- +DynaMedex bundle integrates Micromedex drug information
- +Lower individual pricing than UpToDate ($399/year vs $579/year)
- +Dyna AI generative assistant grounded in curated evidence (launched 2024)
- +EHR integration via HL7 Infobutton and toolbar links
- +CME/MOC credit tracking built in
Limitations
- –Lower brand recognition than UpToDate among physicians
- –Fewer clinical topics than UpToDate (3,400 vs 12,000+)
- –Dyna AI is an add-on cost ($475/year vs $399/year base)
- –AI features are newer and less mature than dedicated CDS platforms
- –Shared decision-making tools (DynaMed Decisions) require separate licensing
- –No free tier for individual physicians
Key Statistics
OpenEvidence
DynaMed
Citable Summaries
OpenEvidence
OpenEvidence has an editorial score of 73/100 (3.7/5), calculated from Clinical AI Report's published criteria weights. It ranks #2 among 7 general clinical decision support tools under this rubric. The score is an editorial assessment, not an aggregate of user reviews or a clinical performance benchmark.
Source: Clinical AI Report, May 2026
DynaMed
DynaMed has an editorial score of 59/100 (3.0/5), calculated from Clinical AI Report's published criteria weights. It ranks #7 among 7 general clinical decision support tools under this rubric. The score is an editorial assessment, not an aggregate of user reviews or a clinical performance benchmark.
Source: Clinical AI Report, May 2026
Our Assessment
In our 2026 evaluation, OpenEvidence (ranked #2, 3.7 stars) outperforms DynaMed (ranked #7, 3 stars) in overall physician satisfaction and editorial scoring. OpenEvidence is best suited for a useful tool for physicians who need fast, cited answers to clinical questions grounded in peer-reviewed literature. Relevant for primary care, internal medicine, and emergency medicine. Free and backed by a broad content partnership network (NEJM, JAMA, NCCN, ACC, AAFP, ACEP). Meanwhile, DynaMed is a stronger choice for physicians and institutions seeking a KLAS-recognized, evidence-graded clinical reference at a lower price point than UpToDate, with integrated drug information via Micromedex. Both tools serve important but distinct roles in clinical care workflows, and physicians should choose based on their specific workflow requirements and institutional needs.